01
Analyst Verdict — FY26 Landmark, FY27 Make-or-Break
✦ Overall Assessment — Structural Inflection Complete
Sai Life Sciences has delivered a landmark FY26: revenue +29%, EBITDA +56%, PAT +109%. More importantly, the deleveraging cycle is complete (Net Debt/EBITDA: 5.6x → 0.04x). The company is now entering its most aggressive investment phase ever — ₹1,100–1,300 Cr capex in FY27 vs ₹633 Cr in FY26. Every concall signal confirms this is demand-pulled, not speculative. The MD explicitly said: "We have a lot of conviction behind these investments." With 19 of top 25 global pharma as clients, 34 commercial molecules, 11 in Phase III, a PEG of 0.29x, and institutional (DII+FII) ownership jumping from 24% → 53% in one year — this stock is being accumulated by the smartest money in the market. Accumulate on dips toward ₹950–1,020. Target 18–24M: ₹1,350–1,550.
FY26 Revenue
₹2,192 Cr
▲ 29% YoY
CDMO +33% · CRO +24%
EBITDA (FY26)
₹661 Cr
▲ 56% YoY
Margin: 30.1% vs 25.1% LY (+508 bps)
PAT (Adj.)
₹355 Cr
▲ 109% YoY
PAT margin: 16.2% — first time ever this high
Q4 FY26 Revenue
₹602 Cr
▲ 3.8% YoY
CFO explained: FY25 Q4 was 34% of full-year; FY26 Q4 only 27%
Q4 EBITDA Margin
31%
▲ 300 bps YoY
QoQ dip from 34% in Q3 — employee cost surge
Net Debt/EBITDA
0.04x
▼ from 5.61x (FY22)
Nearly debt-free — historic transformation
ROCE (FY26)
18.2%
▲ from 12.3%
5yr journey: 3.2% → 18.2%
FY27 Capex
₹1,200 Cr
▲ ~2x FY26
65% CDMO / 35% CRO split confirmed
Large Pharma Revenue %
49%
▲ from 28% (FY22)
Top 19 of global top 25 now customers
Institutional Holding
52.8%
▲ from 23.7%
DII 31.4% + FII 21.4% — massive accumulation
02
Concall ↔ PPT: What Was Said vs What the Numbers Show
🔗 Analyst Framework — Reading Between the Lines
This is the most critical section. PPTs are curated documents. Concalls are live, unscripted, and reveal real conviction levels, hesitations, and gaps. Below I've mapped every major concall statement to the underlying financial data and identified where management is being forthright, where they're hedging, and where the numbers reveal something the words don't.
| Topic | PPT Claim | Concall Detail (What Was Actually Said) | Analyst Read — Gap or Confirm? | Signal |
|---|---|---|---|---|
| Revenue Growth | 29% revenue growth; H1/H2 split 48/52% | CFO: "FY25 Q4 was 34% of total revenues vs 27% in FY26." Explained lumpiness explicitly. Said business can't be ascertained quarter to quarter. "You produce only based on what the customer wants." | Q4 slowdown (4% YoY) is NOT a red flag — FY25 Q4 was anomalously high base. H1/H2 balancing is actually healthier than FY25's 40/60 skew. Full-year growth is the only metric to track. | CONFIRM |
| Margin Guidance | 28–30% EBITDA maintained over 3-year period | MD: "With pharma there is open book pricing... margins tend to remain 25–30%... there's going to be some inefficiency as we scale up new capacity." CFO: "28–30% is our steady state aspiration. We actually committed we'd get there in 2–3 years and we've gotten to 30% last year." | Critical read: "Open book pricing" means margin is contractually capped with large pharma — not discretionary. They're not targeting 30%+; they're targeting SUSTAINING 28–30% while absorbing ₹1,200 Cr capex ramp. Q4's 31% = peak. FY27 likely 27–29%. | WATCH |
| Capex ₹1,100–1,300 Cr | FY27 capex guidance; 75% capacity, 25% capability+AI | Morgan Stanley asked: "Is there any one-off project or is this a new level?" MD: "Based on what customers are telling us, is where we have to go." CFO: "We will continue to calibrate the pace and phasing." Debt guidance: "Debt/EBITDA will be fairly healthy" — no absolute number given. | Management REFUSED to give debt projection. This is the single biggest read-between-the-lines moment. OCF ~₹700 Cr vs ₹1,200 Cr capex = ₹500 Cr gap = NEW DEBT. They deliberately avoided quantifying. Ask this in next call. | PROBE |
| New Commercial Molecules | 34 commercial molecules (up from 30); 11 in Phase III | CFO: "At least three molecules will show good progress and start delivering revenue in fiscal 27. The fourth is smaller but an important capability acquisition." On Phase III: "Some have just moved in and it's very difficult to predict commercialization." | 3 of 4 new molecules will generate revenue in FY27. This is an explicit near-term revenue commitment from the CFO. Phrase "important capability acquisition" on the 4th molecule hints at new modality entry (ADC or peptide). Not disclosed for confidentiality. | BULLISH |
| Phase III Ramp (6→11) | Phase III / pre-reg jumped from 6 (Q3) to 11 (Q4) | Kotak analyst probed: "Seems like you've added ~5 incremental Phase III in one quarter?" MD: "Most are small molecules. Some from integrated CDMO play where pharma is consolidating late-phase outsourcing to India. One or two from new modalities." On FY28 commercialization: "Very difficult to predict but we'll come back." | 5 Phase III additions in ONE QUARTER is extraordinary. This suggests large pharma is rapidly accelerating India-based late-phase development outsourcing. The integrated CDMO strategy is bearing fruit faster than guided. Phase III → commercial is the silent revenue bomb for FY28–29. | VERY BULLISH |
| New Modalities (4%→7%→4%) | New modalities at 4% of revenue in FY26 | Q: "New tech revenue went from 7% to 4% — even in absolute terms a decline?" CFO: "Work on new modalities is in CLINICAL pipeline, not commercial. Campaigns happen and then you wait. This is the primary reason CDMO businesses have revenue lumpiness." | Clarified and satisfactory. The 4% is not a strategic retreat — it's campaign timing. Clinical-stage ADC/peptide/oligo programs by definition are lumpy. FY25's 7% likely included a major campaign that completed. The underlying pipeline is growing. Management declined to give target for FY30. | NEUTRAL |
| Customer Concentration | Top 1 customer = 12%, Top 5 = 37%, Top 10 = 54% | MD proactively disclosed concentration data — unusual transparency. Added: "Our top customer engagement spans multiple services, reducing cost risk at any service level." On naming customers: "We will not be able to due to confidentiality." | 54% from top 10 is concentrated but healthy for CRDMO — each customer is likely a global top-25 pharma with 10+ year relationships. The "multiple services" hedge is real — a customer using Discovery + Development + Commercial is far stickier than one in only manufacturing. Top-1 at 12% warrants monitoring. | MONITOR |
| Large Pharma Strategy | 19 of top 25 global pharma; revenue contribution 49% | MD: "Companies want to develop strategic partners in India at this point. They want to see who will be relevant in the next 5 years." Added 1 new top-25 pharma client this quarter (18→19). Dedicated development R&D team model with large pharma scaling — "late and mid-stage development agreements." | The Dedicated R&D Team Model is the stealth strategic development of FY26 — management clarified it's NOT a dedicated facility (investor confusion) but dedicated Sai teams running late-stage development for large pharma. This is higher-margin, longer-duration, and more data-rich than traditional CDMO. | BULLISH |
| Tariff / Geopolitics | Monitoring global trade; Middle East disrupting logistics | CFO: "Increases in input costs and higher logistics costs… the recovery of these may not always be contemporaneous with the incurrence of costs." MD on tariffs: "Large pharma are increasingly structuring deals to mitigate tariff exposure." | Two distinct risks conflated in PPT. (1) Middle East = input cost + logistics headwind — REAL, already impacting. (2) US tariffs = being mitigated by pharma via deal structuring — manageable. CFO's "not contemporaneous" admission is critical: there WILL be a margin lag before costs are recovered from customers. | RISK |
| AI Strategy | Investing in AI for productivity; 25% of capex on capability/AI | MD: "We are not a single tool. It's a complete way of operation that has to change." Seconded: "Unless you get the platform right, you won't be able to apply tools across the board." On customer data: "We are restricted in what we can use." Building an "AI canvas" internally. CFO: "Anything we build or buy = CapEx." | AI investment is real but early-stage and constrained by customer IP. The "AI canvas" is an internal productivity tool, not a drug discovery AI platform. This is smart — they're building the data infrastructure now so they can plug-and-play AI tools as they mature. Don't overweight AI as a near-term revenue driver. | FOUNDATIONAL |
| Asset Turnover | Strong capital efficiency; growing capacity | CFO on asset turns: "Net basis 1.2–1.4 medium-term. Would see some fluctuations as we double down on CapEx." MD: "It takes 2–3 year cycle to get back to scale after any CapEx. Revenue doesn't come day one." | Explicit 2–3 year payback warning. Current asset turnover ~1.2x. With ~₹1,300 Cr additional gross block in FY27, net FA will jump from ₹1,534 Cr to ~₹2,700 Cr. At 1.2x turns, this requires ₹3,240 Cr revenue. That aligns with FY28E/FY29E targets — but there WILL be a 1–2 year dilution dip. | WATCH |
| H2 FY27 Stronger | H2 FY27 expected stronger than H1 | MD (closing remarks): "Given some of our new capacities and investment progressively coming on stream during the year, we expect the second half of FY27 to be stronger than the first half." | Guidance for H1 FY27 softness is explicit. Q1/Q2 FY27 will likely see margin pressure (capex ramp costs without full revenue). Q3/Q4 FY27 should show recovery. This sets up a H1 disappointment risk if analysts build in straight-line growth. Buy H1 dips strategically. | TACTICAL |
03
P&L — Line by Line with Concall Commentary
| Particulars (₹ Cr) | Q4 FY26 | Q3 FY26 | Q4 FY25 | YoY % | QoQ % | FY26 | FY25 | YoY % |
|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 602 | 556 | 580 | +3.8% | +8.3% | 2,192 | 1,695 | +29.3% |
| ONE-OFF Incl. ₹34 Cr provision reversal (destocking) | — | — | — | — | — | ~34 | — | Clean: ₹2,158 Cr |
| Materials Cost | 162 | 128 | 168 | -3.6% | +26.6% | 571 | 466 | +22.5% |
| Material Margin % | 73.1% | 77.0% | 71.0% | +210 bps | -390 bps | 73.9% | 72.5% | +140 bps |
| WATCH Employee Benefits Expense | 187 | 173 | 151 | +23.8% | +8.1% | 683 | 549 | +24.4% |
| Employee Cost as % Revenue | 31.1% | 31.1% | 26.0% | +510 bps | Flat | 31.2% | 32.4% | -120 bps |
| Other Expenses | 77 | 68 | 103 | -25.2% | +13.2% | 307 | 274 | +12.0% |
| Forex (Gain) / Loss | -12 | -3 | -3 | Gain ↑ | Gain ↑ | -30 | -19 | Gain ↑ |
| EBITDA | 189 | 191 | 161 | +17.4% | -1.0% | 661 | 425 | +55.5% |
| EBITDA Margin | 31.4% | 34.4% | 27.8% | +360 bps | -300 bps | 30.1% | 25.1% | +508 bps |
| Finance Costs | 8 | 10 | 11 | -27.3% | -20.0% | 39 | 76 | -48.7% |
| Depreciation & Amortisation | 45 | 44 | 37 | +21.6% | +2.3% | 167 | 139 | +20.1% |
| PBT (excl. exceptional) | 139 | 142 | 119 | +16.8% | -2.1% | 474 | 228 | +107.9% |
| ONE-OFF Exceptional Item (wage definition change) | 0 | 8 | 0 | — | — | 8 | 0 | — |
| Tax (effective rate ~25%) | 35 | 34 | 31 | +12.9% | +2.9% | 117 | 58 | +101.7% |
| PAT (Reported) | 104 | 100 | 88 | +18.2% | +4.0% | 349 | 170 | +105.3% |
| PAT (Adj., excl. exceptional) | — | — | — | — | — | 355 | 170 | +108.8% |
| EPS (Basic, ₹) | 4.96 | 4.75 | 4.24 | +17% | +4.4% | 16.90 | 8.16 | +107% |
⚡ Line-by-Line Auditor Flag: 4 Items Need Deeper Scrutiny
1. ₹34 Cr provision reversal — boosted FY26 revenue by ~1.5%. Clean underlying revenue is ₹2,158 Cr (+27% YoY). CFO mentioned "commercial product destocking" customer renewed — demand is real. But this is a one-time catch-up, not structural. 2. Forex gain ₹30 Cr — structurally volatile. USD/INR was favorable. FY27 could reverse. 3. Employee cost QoQ — ₹173 Cr (Q3) → ₹187 Cr (Q4) despite flat revenue from Q3. Hiring ahead of FY27 capacity ramp-up. This is intentional but suppresses near-term margins. 4. Exceptional ₹8 Cr — "wage definition change" is likely a labour law reclassification. Not expected to recur — but signals regulatory compliance costs may creep up.
"The CDMO sector is inherently characterised by a degree of quarterly lumpiness, particularly as projects transition across different stages. While this will lead to periodic fluctuations in revenue and margin, the long-term opportunity for the CDMO sector remains robust."
— CFO, Q4 FY26 Earnings Call
✦ Analyst Read: This is the CFO setting up not to be held accountable for Q1/Q2 FY27 weakness. It's also factually correct — CDMO businesses simply cannot be evaluated quarterly. The critical question is: has the FULL YEAR trajectory been sustainable? FY26 answers: yes, emphatically.
"You produce only based on what the customer wants. So it just depends on how the PO is... kind of difficult to say when a campaign becomes due and when the PEO gets delivered."
— MD, responding to Q4 slowdown question
✦ Analyst Read: This explains why Q4 at ₹602 Cr looks muted vs Q4 FY25's ₹580 Cr. The comparison was already elevated. The CFO revealed FY25 Q4 was 34% of full-year — which means the PRIOR Q4 base was already front-loaded. The H1/H2 ratio normalizing to 48/52 is structurally healthier for investors.
04
Margin Analysis — The 508 bps Expansion & Its Durability
📊 5-Year EBITDA Margin Journey
FY22
14.5%
14.5%
FY23
16.0%
16.0%
FY24
20.0%
20.0%
FY25
25.1%
25.1%
FY26
30.1%
30.1%
Each year, margins expanded by ~500 bps — a 5yr streak unbroken since FY22. The structural drivers: scale leverage on employee base, material efficiency, and operating leverage on fixed costs. FY26 is likely the peak rate of expansion — FY27 must absorb capex inefficiency.
🔬 FY26 Margin Bridge: 508 bps Breakdown
Material ↑
140 bps
+140 bps
Emp. Lever.
130 bps
+130 bps
Other Exp.
238 bps
+238 bps
Finance ↓
Non-EBITDA
Forex Gain (FY26)
₹30 Cr
⚠ Volatile, not structural
FY27E EBITDA Target
28–30%
Management guidance maintained
"With pharma, generally there's open book pricing. From what we've seen across Chinese companies operating at much larger scale, the margins tend to remain between 25–30%. Our pricing with pharma indicates 28–30% is what is much more comfortable from a pharma pricing perspective. There will also be some amount of inefficiency as we scale up new capacity."
— MD, Q4 FY26 Concall (margin guidance question)
✦ This is the most important concall statement for investors. "Open book pricing" = pharma knows Sai's cost structure. This structurally caps margins — Sai cannot expand margins beyond 30% with large pharma clients because customers would renegotiate. The 28–30% is a contractual/strategic ceiling, not a floor. The implication: Sai's earnings growth MUST come from revenue scale, not margin expansion. Volume is the only lever. This makes the capex case even more critical.
🔗 Concall ↔ Numbers Connect: Q4 Margin Dip Explained
Q4 EBITDA margin fell 300 bps QoQ (34% → 31%). The concall reveals three drivers: (1) Employee cost jumped ₹14 Cr QoQ as new hires for FY27 capacity came on board in Q4 (per MD: "Science led capacity expansion" → headcount precedes revenue). (2) Middle East logistics costs in Q4 specifically elevated. (3) Q3 had a ₹3 Cr forex gain vs Q4's ₹12 Cr — but even stripping this, Q4 underlying margins compressed. The Q4 dip is a leading indicator of FY27 H1 pressure, not a random fluctuation.
05
Balance Sheet — Transformation Complete, Watch the Rebuild
Total Equity
₹2,484 Cr
▲ ₹356 Cr YoY
PAT accretion + IPO proceeds retained
Net Borrowings
~₹15 Cr
▼ from ₹928 Cr (FY24)
Virtually debt-free. FY27 will reverse this.
Cash & Bank
₹111 Cr
▼ from ₹464 Cr
IPO proceeds deployed. Thin buffer for ₹1,200 Cr capex.
CWIP
₹270 Cr
▲ +118% YoY
Unit 2 Hyd + Bidar expansion underway
Net Fixed Assets
₹1,534 Cr
▲ 29.5% YoY
Asset turnover: 1.2x — in line with guidance
Other Current Assets
₹624 Cr
▲ +28% YoY
⚠ Jumped ₹137 Cr — advance capex payments + deferred billing
Trade Receivables
₹374 Cr
Stable
Debtor days: ~62 days. Blue-chip debtors.
Working Capital Days
105 days
▼ from 219 days (FY22)
Structural improvement
⚠ Most Important BS Risk: The FY27 Cash Gap
Cash: ₹111 Cr. Planned capex: ₹1,100–1,300 Cr. Expected OCF: ~₹700–750 Cr. Gap: ~₹400–550 Cr must come from NEW DEBT. The CFO explicitly refused to quantify the debt level — saying only "debt/EBITDA will be fairly healthy." ICRA's AA(Stable) rating (Feb 2026) and the CFO's implied confidence suggest debt/EBITDA will stay below 1.5x. But after 4 years of deleveraging celebration, investors must mentally prepare for Sai to carry debt again in FY27–28. This is fine if EBITDA growth justifies it — but the narrative shift from "debt-free" to "leveraged for growth" could cause a sentiment dip even if fundamentals are intact.
| Balance Sheet Item (₹ Cr) | Mar 2026 | Mar 2025 | Change | Analyst Comment |
|---|---|---|---|---|
| PPE (Net Fixed Assets) | 1,534 | 1,185 | +29.5% | Growing in sync with ₹633 Cr capex; will accelerate sharply in FY27 |
| CWIP (Capital Work in Progress) | 270 | 124 | +117.7% | More than doubled — Bidar Plant 2 + Hyd Unit 2; watch commissioning timelines |
| Intangibles & Goodwill | ~22 | ~18 | +22% | Stable — no M&A premium buildup yet. M&A remains "evaluating" stage |
| Inventories | 151 | 119 | +26.9% | Building ahead of revenue ramp. Inventory days: ~25 days. Fine. |
| Trade Receivables | 374 | 355 | +5.4% | Grew slower than revenue — improving debtor days. Blue-chip pharma = quality debtors |
| Cash & Bank (incl. MFs) | 111 | 464 | -76.1% | ⚠ ALERT: IPO proceeds deployed. Thin buffer. New debt in FY27 confirmed. |
| Other Current Assets | 624 | 487 | +28.1% | ⚠ Unexplained ₹137 Cr jump — likely advance capex, unbilled, or prepaid contracts. Needs Q1 disclosure. |
| Total Borrowings (LT+ST) | 96 | 129 | -25.6% | ✓ Continues to decline. But watch FY27 — debt will rebuild. |
| Trade Payables | 285 | 323 | -11.8% | Reduced — vendor payments normalized post-destocking resolution |
| Deferred Tax Liability | 128 | 111 | +15.3% | Consistent with accelerated depreciation on expanded fixed assets |
| Book Value per Share (₹) | ~118 | ~101 | +16.8% | P/B: 9.2x — rich but ROCE inflection justifies premium |
06
Business Segments — The CRO→CDMO Flywheel
🏭 CDMO — Manufacturing Engine (65% of Rev)
₹1,417 Cr
FY26 Revenue
▲ 33% YoY
34
Commercial Molecules
+4 in FY26
- 94% of CDMO revenue from large pharma (vs 91% FY25) — biotech share shrinking in CDMO, a quality positive
- 3 of 4 new molecules will generate commercial revenue in FY27 — CFO's explicit commitment on concall
- Two new large pharma commercial supply qualifications — most underreported disclosure; locks in future revenue
- Phase III jumped from 6→11 in one quarter — 5 additions; pharma accelerating late-phase outsourcing to India
- Therapy mix: CNS 25%, Infectious Diseases 16%, Oncology 15%, Others 44%
- Dedicated Development R&D team model scaling — "late and mid-stage development agreements" with large pharma
🔗 Concall Connect: What "Commercial Supply Qualifications" Really Means
When a large pharma qualifies Sai as a commercial supplier, this typically involves a multi-year audit + validation process. The fact that two new qualifications happened in FY26 means revenue from these customers could start in FY27–28, grow for 5–10 years, and is extremely sticky. This is not a one-time order — it's a relationship lock-in. Management couldn't name the molecules (confidentiality) but this is potentially the most valuable disclosure in the entire PPT.
🔬 CRO/Discovery — Lead Generation Engine (35% of Rev)
₹775 Cr
FY26 Revenue
▲ 24% YoY
200+
Discovery Clients
Growing
- CRO Pharma:Biotech = 48:52 (vs 52:48 FY25) — biotech now majority. Watch funding risk
- Biotech funding up 52% YTD — management disclosed April 2025 was ₹10.6B globally, up 4% YoY. Positive signal
- >65% of programs are integrated (multi-service) — higher stickiness, bigger wallet share
- HTE (High Throughput Experimentation) platform operational — enables bigger, faster integrated programs
- DMPK + Biology automation scaling — "precision biology at volume" is the moat being built
- "Sci Academy" launched — internal training headed by a former large pharma senior research head
🔗 Concall Connect: CRO is the CDMO Pipeline Factory
MD explicitly explained: "Every large pharma is now looking at coming to India through discovery. 3 years ago, only 2–3 large pharma were doing med-chem in India. Now every large pharma is looking." This structural shift means CRO growth is not biotech-funded (volatile) but large-pharma-funded (stable, long-cycle). As large pharma discovery in India scales, it feeds development, which feeds commercial manufacturing at Sai. The CRO-to-CDMO flywheel is a 5–8 year lag business — seeds planted in FY26 CRO are CDMO revenue in FY32–33.
07
Capex — The Defining Variable for FY27–FY29
⚡ Capex is Where Conviction Gets Tested
₹1,100–1,300 Cr capex in FY27 — nearly double FY26's ₹633 Cr and the largest single-year spend in Sai's history. The Morgan Stanley analyst probed the key question: is this a one-off or a new run rate? MD: "This is not a one-off. Based on what customers are telling us, this is where we have to go." The CFO further clarified that 225 KL of the 700→1,150 KL CDMO expansion will come online in H2 FY27, with the remaining 225 KL in FY28. Plus a new greenfield site at Choutuppal — likely FY28–29 revenue optionality.
🏗 FY27 Capex Allocation (₹1,200 Cr midpoint)
Capacity Exp.
75% = ₹900 Cr
₹900 Cr
Capability+AI
25% = ₹300 Cr
₹300 Cr
By Segment
CDMO (65%)
₹780 Cr
₹780 Cr
CRO (35%)
₹420 Cr
₹420 Cr
📋 Specific Capacity Additions (from Concall)
CDMO: 700 KL → 1,150 KL (225 KL in H2 FY27 + 225 KL in FY28).
Discovery: Doubling R&D capacity (fume cupboards, analytics, biology equipment).
New Modalities: Peptide pilot scale coming FY27; ADC development capability adding; HTE biology platform expanding.
Greenfield (Choutuppal): ₹"slightly smaller CapEx" starting late FY27 — land acquired, FY29–30 revenue optionality.
💰 Capex Funding — The Math
| Item | ₹ Cr |
|---|---|
| FY27 Capex (Midpoint) | 1,200 |
| Expected OCF (FY27E) | ~700 |
| Cash on Balance Sheet | 111 |
| Gross Funding Gap (before cash) | ~389 |
| Estimated New Debt Required | ~280–400 Cr |
| Projected YE FY27 Net Debt | ~300–400 Cr |
| FY27E EBITDA (~₹750 Cr) | ~750 |
| Implied Net Debt/EBITDA FY27E | ~0.5x |
✓ Even with debt rebuild, Net Debt/EBITDA stays well below 1x. CFO's "fairly healthy" language now has a number: ~0.4–0.5x. This is comfortable and ICRA AA(Stable) confirms lender confidence.
"Companies want to develop strategic partners in India at this point. They want to see who will be relevant in the next 5 years. And they want to see partners who can understand, work with them and build along with them. That's how we're playing this game. So we have a lot of conviction behind these investments."
— MD (Krishna), responding to Morgan Stanley's capex confidence question
✦ "A lot of conviction" is unusually strong language from a MD in a public forum. He's staking his credibility on this capex cycle. The fact that pharma is giving visibility — not just RFPs, but access to pipeline visibility — is what's changed. This is why capex jumped from ₹200 Cr two years ago to ₹1,200 Cr: the customer conversations changed, not the ambition.
08
Customer Quality & Concentration — The 54% Question
🎯 Customer Concentration (FY26 — First Time Disclosed)
Top 1 Customer
12%
12%
Top 5 Customers
37%
37%
Top 10 Customers
54%
54%
Large Pharma (19)
49%
49%
Analyst Note: Top-1 at 12% is the concentration risk number to watch. MD deliberately disclosed this — transparency is positive. But a single customer at 12% of ₹2,192 Cr = ₹263 Cr. Any disruption there would hit quarterly numbers visibly.
🌐 Customer Quality Metrics
- 19 of top 25 global pharma — average revenue/pharma customer: ~₹56 Cr. Significant and growing.
- Average relationship tenure: 11+ years — these are not opportunistic relationships
- Top customer uses multiple services (Discovery + Development + Manufacturing) — near-impossible to switch easily
- Dedicated Development R&D Team model — only a few Indian CRDMOs have achieved this with large pharma
- FY22: 28% large pharma → FY26: 49% — this is the most important strategic shift in 4 years
- New 19th top-25 pharma customer added Q4 FY26 — pipeline growing
🔗 Concall: Why Large Pharma is Coming to India Now
MD: "3 years back, only 2–3 large pharma were actively doing med-chem in India. Now EVERY large pharma is looking at coming to India through discovery." This structural shift is being driven by China+1, regulatory scrutiny of Chinese supply chains, and cost efficiency. Sai is among the 2–3 Indian CRDMOs positioned as Tier 1 partners. This is a generational opportunity window — FY26–FY30 may define the India CRDMO competitive landscape for the next decade.
09
Pipeline — The Hidden Revenue Bomb
Commercial Molecules
34
+4 in FY26
3 of 4 new ones generating FY27 revenue
Phase III / Pre-Reg
11
▲ from 6 (Q3 FY26)
+5 in one quarter — extraordinary
Early Stage (Phase I/II)
155
Future commercial pipeline over 5–10 years
Active Customers (Innov.)
200+
CRO discovery funnel
Commercial Molecules
FY25: 30
+4 added; process: validate → qualify → commercial
🧬 Pipeline Progression Economics
- Discovery → Phase I: 5–8% success rate. Sai is at the top-of-funnel generating 200+ programs
- Phase I → Phase III: ~15% success. Of 155 early-stage, statistically ~23 will reach Phase III
- Phase III → Commercial: ~60% success. Of 11 in Phase III, ~7 will commercialize
- Revenue per commercial molecule (rough estimate): ₹30–150 Cr/yr depending on volume and therapy area
- FY26 commercial revenue at 34 molecules: ~₹1,417 Cr CDMO / 34 = ~₹42 Cr average/molecule/yr
- If 7 of 11 Phase III commercialize over FY28–30: potential ₹200–400 Cr incremental annual revenue
🔑 New Modalities Pipeline
- Peptides: Pilot scale coming FY27; fragment commercial supply as entry point; CapEx confirmed
- ADCs: Class 6 containment planned; discovery capability adding; development timeline unclear — "will announce when ready"
- Oligonucleotides: Multi-pharma projects; amidites focus; already generating some revenue
- Lipids: "Active supplier for several years" — established but not highlighted
- Biologics (future): "We evaluate all options. Will communicate when ready." — optionality preserved
🔗 Concall: Why New Modalities Revenue Went 7%→4%
CFO: "A lot of new modality work is in clinical pipeline, not commercial. You have a campaign, then you wait for another campaign — this lumpiness is the primary reason CDMO businesses have lumpy revenue streams." This means the 4% in FY26 is NOT a strategic retreat. Clinical-stage peptide or ADC programs run in batches — when the trial needs material, revenue spikes; when not, it drops. Underlying pipeline is growing. Next campaign spike could be in any quarter.
10
AI Strategy — Opportunity, Not a Threat (Deep Concall Read)
🤖 What Sai's AI Strategy Actually Is
- "AI Canvas" — internal platform aggregating data for chemists, team leads, and leadership to analyze in real time
- Productivity + efficiency tools — route design, lab-to-plant translation, data correlation; not drug discovery per se
- Partnership data integration — working to integrate with large pharma's systems for seamless data exchange
- "AI native company" — MD's framing: digital platform is the foundation; AI tools plug in on top
- "Sci Academy" — internal learning institution headed by former large pharma senior researcher
- 25% of capex (₹300 Cr) going to capability including AI tools, HTE, automation, fume cupboards
⚖ AI: Threat or Opportunity for Sai?
"AI is creating things without a constraint — it is creating more work on the synthesis side. The design part is what's affected most, not the synthesis. Synthesis is going to be an important aspect. AI for us is a net positive because complexity of molecules is higher and R&D dollars won't drop."
— MD, responding to Kotak analyst on AI in drug discovery
✦ This is the most nuanced AI answer in any Indian CRDMO concall. MD is saying: AI makes molecule design faster, but the AI-designed molecules are MORE COMPLEX to synthesize. More complex = more outsourcing = more revenue for Sai. The synthesis bottleneck is Sai's competitive moat — and AI is making that bottleneck more valuable, not obsolete.
11
Bull & Bear Case — Full Concall-Informed Assessment
✅ 12 Green Flags (Concall-Confirmed)
Phase III molecules jumped 6→11 in one quarter. MD confirmed 2 are new modalities. 5 additions in 90 days is extraordinary velocity.
3 of 4 new commercial molecules generating FY27 revenue. CFO's explicit commitment — rare for management to go this specific.
2 new large pharma commercial supply qualifications. Locks in multi-year, sticky, high-volume revenue from top-25 pharma.
Large pharma revenue 28%→49% in 4 years. Structural quality improvement — less volatile, longer duration, higher margin stability.
DII+FII holding 24%→53% in 12 months. Domestic MFs + global funds are buying aggressively. Smart money is accumulating.
PEG 0.29x on 109% PAT growth. Market is not pricing in the growth trajectory. 3-yr PAT CAGR has been extraordinary.
ROCE inflecting sharply: 3.2%→18.2% in 4 years. Capital is being deployed productively. FY28 could see 20%+.
Net Debt/EBITDA: 5.6x→0.04x. Balance sheet transformation complete — entering capex from a position of financial strength.
Biotech funding up 52% YTD (per MD). CRO's biotech revenue segment (48% of CRO) has a strong macro tailwind returning.
ICRA AA(Stable) rating (Feb 2026). Opens low-cost long-term debt access for FY27 capex. Debt at ~7% vs ROCE of 18%+.
AI is a net positive for Sai (per MD). Complex AI-designed molecules create MORE synthesis work — Sai's core moat strengthens, not weakens.
H1/H2 seasonality normalizing. FY26's 48/52 split vs FY25's 40/60 means Sai's revenue is more predictable and less back-loaded.
⚠ 10 Red Flags (Concall-Identified Risks)
CFO refused to quantify FY27 debt. "Fairly healthy" is deliberately vague. ~₹300–400 Cr new debt incoming. Narrative shift from "debt-free" matters for retail sentiment.
"Cost recovery not contemporaneous." CFO explicitly said Middle East cost increases may not be recovered from customers at the same time. Margin squeeze risk in H1 FY27.
Employee cost at 31% of revenue in Q4. Growing faster than revenue in the last 2 quarters. Pre-hiring for FY27 capacity is intentional but margin-dilutive.
Top-1 customer = 12% of revenue. ~₹263 Cr from one customer. Any supply disruption, clinical trial failure, or relationship change = visible quarterly miss.
New modality revenue went 7%→4%. Explained as campaign timing — but we have no forward visibility. Could stay at 4% for 2–3 more quarters.
Cash fell ₹464→111 Cr. With ₹1,200 Cr capex ahead, Sai is effectively FCF-negative in FY27. Dividend probability: zero.
Other Current Assets up ₹137 Cr (unexplained). "Advance capex payments or deferred billing" — needs explicit Q1 FY27 disclosure. Quality of earnings concern.
H1 FY27 will be weaker. MD guided H2 FY27 stronger. This means Q1/Q2 FY27 results may disappoint investors expecting straight-line growth from FY26's strong Q4.
Asset turnover will dip. CFO warned: "Some fluctuations before it comes back." With gross block jumping from ₹1,534 Cr to ~₹2,700 Cr, turns will dilute for 2–3 years. Watch ROCE dip before recovery.
No Phase III commercialization timeline given. 11 in Phase III but management said "very difficult to predict." The Phase III→commercial revenue could be FY28 or FY30 — timing risk is material.
12
5-Year KPI Scorecard — The Full Journey
| KPI | FY22 | FY23 | FY24 | FY25 | FY26 | FY27E | Verdict |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 870 | 1,217 | 1,465 | 1,695 | 2,192 | 2,600–2,800 | ✅ 5yr CAGR: ~26% |
| EBITDA (₹ Cr) | 131 | 182 | 300 | 425 | 661 | 730–840 | ✅ Accelerating |
| EBITDA Margin | 14.5% | 16% | 20% | 25.1% | 30.1% | 28–30% | ⚠ Guided hold; near-term pressure |
| PAT (₹ Cr) | 6 | 10 | 83 | 170 | 355 | 380–450 | ✅ Extraordinary ramp |
| PAT Margin | 0.7% | 0.8% | 5.7% | 10.0% | 16.2% | 14–16% | ✅ Structural step-up |
| ROCE | 3.2% | 5.1% | 10.3% | 12.3% | 18.2% | ~15% | ⚠ May dip FY27 before FY28 recovery |
| ROE | 0.7% | 1.1% | 8.5% | 8.0% | 14.3% | ~16% | ✅ Improving |
| Net Debt/EBITDA | 5.6x | 3.9x | 2.4x | 0.00x | 0.04x | ~0.4–0.5x | ⚠ Debt coming back for capex. OK. |
| Net FA Turnover | 0.9x | 1.2x | 1.2x | 1.1x | 1.2x | ~0.9–1.0x | ⚠ Will dilute as new capacity added |
| Working Capital Days | 219 | 144 | 124 | 121 | 105 | ~100 | ✅ Structural improvement |
| Large Pharma Revenue % | 28% | 35% | 42% | 45% | 49% | 52%+ | ✅ Highest quality revenue mix |
| Commercial Molecules | 22 | 26 | 28 | 30 | 34 | 37–39 | ✅ Pipeline growing reliably |
13
Valuation — Is ₹1,089 Cheap or Dear?
Market Cap
₹23,069 Cr
At CMP ₹1,089 (May 2026)
EV (Est.)
~₹22,850 Cr
Mkt Cap + net debt ~₹15 Cr
P/E (FY26 Adj.)
65x
₹355 Cr PAT. Elevated but growing fast
EV/EBITDA (FY26)
34.6x
₹661 Cr EBITDA. Peers: 30–45x
P/E (FY27E Fwd)
~50x
If PAT = ₹450 Cr. Reasonable for growth
PEG Ratio
0.29x
Based on 3-yr PAT CAGR. Deeply attractive
P/Sales (FY26)
10.5x
₹2,192 Cr rev. Premium justified
P/Book (FY26)
9.2x
₹2,484 Cr equity. ROCE inflecting justifies
DCF Fair Value Est.
₹1,250–1,450
15% WACC, 18% FCF CAGR, 10yr. Upside: 15–33%
📈 Bull Case — FY28E (₹3,000 Cr Revenue)
- Revenue: ₹3,100 Cr (20% CAGR from FY26)
- EBITDA Margin: 30% → EBITDA: ₹930 Cr
- D&A: ~₹280 Cr (capex step-up absorbed)
- Finance Cost: ~₹60 Cr (debt ~₹600 Cr)
- PAT: ~₹440 Cr
- At 45x FY28E P/E → Target ₹1,940/share (+78%)
- At 40x FY28E P/E → Target ₹1,720/share (+58%)
- Requires: Phase III pipeline conversions, FY27 capex commissioned on time
📉 Bear Case — FY28E (Execution Slip)
- Revenue: ₹2,700 Cr (11% CAGR — ramp-up delayed)
- EBITDA Margin: 26.5% (margin pressure from ramp + costs)
- D&A: ~₹310 Cr (capex-led depreciation spike)
- Finance Cost: ~₹90 Cr (debt higher than expected)
- PAT: ~₹270 Cr
- At 35x P/E → Target ₹765/share (-30%)
- Requires: Multiple simultaneous failures (capex delay + margin miss + biotech funding reversal)
- Low probability but non-zero — H1 FY27 is the key watch period
📐 Analyst's Base Case 18–24 Month Target
Target: ₹1,350–1,480 (24% – 36% upside from CMP ₹1,089). Basis: FY27E PAT ₹420 Cr × 40x forward P/E = ₹1,500/share discounted for H1 execution risk = ₹1,350–1,480. Catalyst: Q3 FY27 (Oct-Nov 2026) — when H2 ramp becomes visible and Phase III conversions are announced. Risk: Q1 FY27 results (Aug 2026) — if margins slip below 27%, watch for a correction to ₹950–1,000 — which would be an attractive accumulation opportunity.
14
Forward Outlook — Events, Catalysts & Risks
⚠
Q1 FY27 (Aug 2026) — The First Test WATCH
MD guided H2 FY27 stronger. Q1 will be the weakest quarter of FY27. Expect: (1) Revenue ₹560–620 Cr (flat QoQ), (2) EBITDA margin 26–29% (capex ramp costs, Middle East logistics), (3) Employee cost staying elevated. If results surprise positively → strong re-rating. If weak → buy the dip. Key disclosure to watch: new Phase III additions and any commercial supply qualification announcements.
🏗
H2 FY27 Capacity Commissioning CATALYST
225 KL of CDMO expansion coming online in H2 FY27 (700→925 KL). This is the revenue ramp catalyst. Per historical precedent: new CDMO capacity takes 6–12 months to reach utilization. So revenue from new capacity likely starts materializing in Q3/Q4 FY27. EBITDA margins should recover toward 29–30% once utilization scales. Simultaneously: Bidar discovery capacity + HTE biology platform will enable larger integrated programs.
💊
Phase III Pipeline Commercialization (FY28–29) BIG CATALYST
11 molecules in Phase III/pre-registration. If 50–60% succeed (historical base rate), 5–7 new commercial molecules by FY29. At ₹42 Cr average/molecule/yr, this is ₹210–295 Cr of incremental annual revenue — on top of organic growth. This is the "hidden" upside not priced in at 65x FY26 P/E. The timing is uncertain, but the probability is high given the 155-molecule early-stage pipeline feeding this funnel.
🌐
India CRDMO Structural Tailwind (FY27–30) SECULAR
China+1 supply chain diversification. US tariff policy evolving in India's favor (large pharma structuring deals to mitigate tariff exposure per MD). India's regulatory track record improving. Sai specifically positioned as a Tier 1 CRDMO with full-lifecycle capability. The next 3–4 years may define which 2–3 Indian CRDMOs become true global partners vs which remain transactional vendors. Sai is in the former category.
⚡
Key Risks to Monitor RISK
1. Margin squeeze H1 FY27: Middle East logistics costs + pre-hiring costs + new capacity underutilization. 2. Top-1 customer disruption: 12% concentration = single point of failure if clinical trial fails. 3. Capex overrun/delay: New facilities running late = depreciation without revenue = margin miss. 4. Regulatory (USFDA/PMDA): Any inspection observation at commercial manufacturing sites. 5. Biotech funding reversal: If global biotech funding contracts, CRO revenue growth (48% biotech) could slow. 6. Management execution: Scaling from ₹2,200 Cr to ₹3,000+ Cr while managing a 2x capex ramp is organizational stress-testing.
✦ Final Investment Conclusion — ACCUMULATE
Sai Life Sciences at ₹1,089 is a growth stock priced below its growth rate (PEG 0.29x) at an inflection point in its business quality (ROCE 18.2%), balance sheet (net debt-free), and strategic positioning (19 of top 25 global pharma). The concall removes ambiguity around the key concerns: Q4 muted growth is seasonal, Phase III acceleration is real, capex conviction is explicit, and margin guidance is intact. H1 FY27 may be volatile — use it to accumulate. The 18–24 month fundamental case is compelling. Target: ₹1,350–1,480. Risk: ₹950 (execution slip). Base case upside: 25–35%.